Hacker News Reader

This sounds awesome. How might it complement the "visual paired comparison" task of Zola et al. (2013) -- which has been commercialized by Neurotrack -- in helping to identify those at risk of dementia?

Zola, S.M., Manzanares, C.M, Clopton, P., Lah, J.J., and Levey, A.I. (2013). Am J Alzheimers Dis Other Demen. 28(2): 179–184. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3670591/

View on HN

There are many tests to tell you the risk of developing dementia, which is only a "probability" number. Darmiyan's brain maps show (and measure) the actual pathology (neurodegeneration) in the brain, at microscopic resolution.

There is currently no other method to detect and quantify micro-structural abnormality in the brain at presymptomatic stages of dementia, which is one of the main reasons why all clinical trials of Alzheimer's test drugs keep failing, one after another.

Reply on news.ycombinator.com